ClinicalTrials.gg
Status unknownNCT03538990DASH HFUpdated Nov 16, 2018

Effect of DASH Eating Pattern on Heart Failure Outcomes

An interventional study of DASH Eating Pattern in Heart Failure NYHA Class III, sponsored by University of Georgia. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by University of Georgia · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the study is to examine the effect of nutritional intake on cardiometabolic, inflammation, and physical function markers in advanced heart failure patients using a one-group pre-post test design feeding trial. Effects on hemodynamic markers will be assessed in a subsample of patients with implanted hemodynamic monitoring devices (CardioMEMS). The pre-test condition is represented by participants' self-selected diet, and the post-test condition is represented by a prescribed Dietary Approaches to Stop Hypertension (DASH) diet.

02

Conditions studied

  • Heart Failure NYHA Class III

Keywords

  • Nutrition
  • Dietary Approaches to Stop Hypertension
  • Cardiometabolic Outcomes
  • Pulmonary Artery Pressure
  • CardioMEMS
03

In context

Lead sponsor

University of Georgia is the lead sponsor of 74 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18+ years of age
  2. English language literacy
  3. Diagnosis of HF ≥ 3 months
  4. Diagnosis of NYHA Class III HF (historical assessment)
  5. Subjects must be stable on HF medication regimen for one month prior to study entry
  6. At least 1 HF hospitalization within 24 months of enrollment
  7. BNP >200 pg/ml

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have had an unplanned HF-related hospitalization within 2 months of enrollment
  2. Subjects with a Glomerular Filtration Rate (GFR) \<25 ml/min who are nonresponsive to diuretic therapy or who are on chronic renal dialysis
  3. Subjects likely to undergo heart transplantation within 2 months of enrollment
  4. Subjects with severe conditions limiting 6-month survival
  5. Unavailability during scheduled data collection points
  6. Cognitive impairment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    DASH Eating Pattern

    The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. During the intervention phase of the study, all participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.

    Other: DASH Eating Pattern

Interventions

  • OtherDASH Eating Pattern

    The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.

06

What researchers measure

Primary outcomes

  1. Change in Cardiometabolic Marker Levels between Calibration and DASH Diet Intervention Phase

    Change of the following cardiometabolic marker values will be calculated between calibration and intervention phase using repeated measures analysis methods (3 time points over the course of 6 weeks: baseline, mid-point, post-DASH intervention): fasting lipid panel, hemoglobin A1c, basic metabolic panel (sodium, potassium, chloride, carbon dioxide (CO2), blood urea nitrogen, creatinine, and glucose), B-type natriuretic peptide (BNP), N terminal proBNP, troponin 1, mid-regional pro-adrenomedullin (MR-proADM), soluble somatostatin receptor 2 (sST2).

    Time frame: Baseline, week 3, week 6

Secondary outcomes

  1. Change in Functional Exercise Capacity between Calibration and DASH Diet Intervention Phase

    We will compare the change in functional exercise capacity using the American Thoracic Society 6-minute walk test between calibration and intervention phase using repeated measures analysis methods (3 time points over the course of 6 weeks: baseline, mid-point, post-DASH intervention).

    Time frame: Baseline, week 3, week 6

Other outcomes

  1. Change in Inflammation Marker Levels between Calibration and DASH Diet Intervention Phase

    We will compare the change of the following inflammation marker values between calibration and intervention phase using repeated measures analysis methods (3 time points over the course of 6 weeks: baseline, mid-point, post-DASH intervention): interleukin (IL)-1a, IL-1b, IL-6, and tumor necrosis factor alpha (TNF-a).

    Time frame: Baseline, week 3, week 6

  2. Change in Hemodynamic Marker Levels between Calibration and DASH Diet Intervention Phase

    Change in mean hemodynamic marker levels will be calculated by comparing mean values from the calibration (week 1-3) and intervention phase (week 3-6). All patients will be instructed to take daily pulmonary artery pressure home readings for the duration of the study.

    Time frame: week 1-3, week 3-6

07

Study locations

1 of 1 sites recruiting
  • University of Georgia Clinical and Translational Research Unit
    Athens, Georgia 30606, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03538990
Lead sponsor
University of Georgia
Collaborators
Emory University
Responsible party
Elisabeth Lilian Pia Sattler, Ph.D., B.S. Pharm (Assistant Professor, University of Georgia) — Principal investigator
First posted
May 29, 2018
Start date
Nov 15, 2018
Primary completion
Sep 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Nov 16, 2018

Study contacts

Elisabeth L Sattler, PhD, BSPharm
Contact
lilian@uga.edu
706-542-1040
Elisabeth L Sattler, PhD, BSPharm
principal investigator · University of Georgia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion